|Treatments:||Chemotherapy||Hospital:||Ospedale San Gerardo|
Patients: This phase II study involved two hundred and eight women with advanced epithelial ovarian cancer. The median age was 52, ranging from 24-73 years old.
Treatment: Patients were treated with cisplatin, paclitaxel, and epirubicin or cisplatin, paclitaxel, and ifosfamide. These are all chemotherapy drugs
Toxicity: Grade 4 pulmonary thromboembolism and anaphylaxis were each reported in one patient. Other toxicities included anemia, leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia.
Results: The median overall survival was 65 months for patients treated with cisplatin, paclitaxel, and epirubicin, and 51 months for those treated with cisplatin, paclitaxel, and ifosfamide.
Correspondence: Dr. R Fruscio